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Abstract
Background: Delayed or secondary cell death that is caused by a cascade of cellular and molecular processes
initiated by traumatic brain injury (TBI) may be reduced or prevented if an effective neuroprotective strategy is
employed. Microarray and subsequent bioinformatic analyses were used to determine which genes, pathways and
networks were significantly altered 24 h after unilateral TBI in the rat. Ipsilateral hemi-brain, the corresponding
contralateral hemi-brain, and naïve (control) brain tissue were used for microarray analysis.
Results: Ingenuity Pathway Analysis showed cell death and survival (CD) to be a top molecular and cellular function
associated with TBI on both sides of the brain. One major finding was that the overall gene expression pattern suggested
an increase in CD genes in ipsilateral brain tissue and suppression of CD genes contralateral to the injury which may
indicate an endogenous protective mechanism. We created networks of genes of interest (GOI) and ranked the genes by
the number of direct connections each had in the GOI networks, creating gene interaction hierarchies (GIHs). Cell cycle
was determined from the resultant GIHs to be a significant molecular and cellular function in post-TBI CD gene response.
Conclusions: Cell cycle and apoptosis signalling genes that were highly ranked in the GIHs and exhibited either the
inverse ipsilateral/contralateral expression pattern or contralateral suppression were identified and included STAT3,
CCND1, CCND2, and BAX. Additional exploration into the remote suppression of CD genes may provide insight into
neuroprotective mechanisms that could be used to develop therapies to prevent cell death following TBI.
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Background
Traumatic brain injury (TBI) is a major public health prob-
lem in both the civilian and military populations as TBI has
now become a prominent injury in war zones. Of the 1.7
million new TBIs that are sustained annually in the United
States [1], 53,000 result in death [2] while an additional
125,000 leave the affected people with long-term behavioral
deficits [3]. Overall, about 3 million Americans are cur-
rently suffering with chronic effects of TBI [4]. Additionally,
it is estimated that 17–30 % of soldiers returning for Iraq
and Afghanistan have suffered TBIs [5, 6]. Development of
more effective clinical treatments is necessary to reduce the
healthcare and financial burden of TBI. Such development
requires basic experimentation into the mechanisms under-
lying TBI.
Primary damage to cells by TBI may be irreversible and
lead to immediate cell death, however, delayed or second-
ary cell death that is caused by a cascade of cellular and
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molecular processes initiated by the trauma [7–10] may
be reduced or prevented if an effective neuroprotective
strategy is employed. Development of such a strategy
requires an understanding of the molecular environment
in the injured brain so that deleterious molecules and pro-
cesses can be identified and inhibited. A step towards
understanding the molecular response to TBI is examining
gene expression profiles following the injury.
Microarray technology allows for examination of thou-
sands of genes in one assay. The key to using this technol-
ogy is interpreting the resulting gene expression patterns
and using the interpreted data to guide further study. The
development of advanced bioinformatic analysis tools have
aided in deciphering microarray data. One such tool is the
Ingenuity Pathway Analysis (IPA) software program which
uses a database built from published scientific literature to
draw direct and indirect interactions between genes and
to assign genes to specific biological functions, canonical
pathways, and networks [11]. IPA also features a strong
network building component that allows for the creation
and analysis of networks composed of any genes of inter-
est (GOI). We have previously devised a method for using
the initial information that IPA provides and subsequent
network analysis to determine which genes are most sig-
nificant to the inflammatory response following neuronal
injury unilateral controlled cortical impact (CCI) in the rat
[12]. This analysis results in a gene interaction hierarchy
(GIH) where genes of interest are ranked based on the
number of interactions they have with each other. The
theory behind the analysis is that a gene that interacts with
more genes in a particular set of genes has the potential to
influence that set of genes the most.
The current study uses gene expression profiling and
bioinformatic analysis to examine the cell death gene
response 24 h following unilateral CCI. One significant
finding of our previous study was that while inflamma-
tory gene expression was induced on the ipsilateral side
of the brain following TBI, there was a suppression of
inflammatory genes contralateral to the injury [12]. We
believe that this endogenous anti-inflammatory re-
sponse may hold clues for the development of anti-
inflammatory treatments for TBI and other acute brain
injuries. Inflammation resulting from many different
types of acute brain injuries, including TBI and ische-
mic stroke, has been linked to subsequent neuronal cell
death [13–16]. By extension, we believe that under-
standing the post-TBI expression of genes involved in




All animals used in these studies were treated humanely
and with regard for alleviation of suffering and pain and all
protocols involving animals were approved by the IACUCs
of Morehouse School of Medicine and/or The Georgia In-
stitute of Technology prior to the initiation of experimen-
tation. Adult male Sprague–Dawley rats (290–300 g;
Charles River Laboratories International, Inc., USA) were
housed individually in standard plastic cages in a
temperature-controlled room (22 ± 2 °C) on a 12 h reverse
light–dark cycle. Food and water were provided ad libitum.
Controlled cortical impact
Under isoflurane anesthesia, rats received a unilateral
controlled cortical impact (CCI/TBI) using the Pittsburgh
Precision Instruments, Inc. device. A craniotomy was made
with the center 4 mm posterior and 3–4 mm lateral to
bregma using a 6 mm diameter trephan drill bit. The impact
was done at an angle of 15° from vertical with a velocity of
3 m/s to a depth of 2 mm using a 5 mm diameter impact
tip. These parameters were chosen to produce a moderate
injury [17]. The rats were sacrificed 24 h post-injury and the
brains were removed for RNA isolation or histology.
RNA preparation and GeneChip analysis
The ipsilateral hemi-brain tissue at the site of the injury,
the corresponding contralateral hemi-brain tissue, and
naïve (control) brain tissue (n = 3 for each) were used for
RNA isolation. Total RNA was extracted with TRIzol
Reagent (Life Technologies, Rockville, MD, USA) and
cleaned (RNAqueous Kit, Ambion, Austin, TX, USA).
The RNA was prepared for microarray hybridization
with the GeneChip® 3′ IVT Express Kit (Affymetrix Inc.,
Santa Clara, CA, USA) aRNA amplification procedure.
Briefly, total RNA was reverse transcribed to synthesize
first-strand cDNA containing a T7 promoter sequence.
The single-stranded cDNA was converted into a double-
stranded DNA template for transcription. The reaction
employed DNA polymerase and RNase H to simultan-
eously degrade the RNA and synthesize second-strand
cDNA. In vitro transcription generated multiple copies of
biotin-modified aRNA from the double-stranded cDNA
templates (this was the amplification step). aRNA Purifica-
tion removed unincorporated NTPs, salts, enzymes, and
inorganic phosphate to improve the stability of the biotin-
modified aRNA. Finally, the labeled aRNA was fragmented
to prepare the sample for hybridization to GeneChip® 3′
expression arrays [18]. Following fragmentation, 15 μg of
the biotinylated cRNA was hybridized to an Affymetrix
Rat Genome 230 2.0 GeneChip. The chips were hybrid-
ized at 45 °C for 16 h, and then washed, stained with
streptavidin–phycoerythrin and scanned according to
manufacturing guidelines.
Microarray data analysis
Data analysis was performed using Affymetrix Expression
Console™ software that supports probe set summarization
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and CHP file generation of 3′ expression using the MAS5
Statistical algorithm. Affymetrix microarrays contain the
hybridization, labeling and housekeeping controls that
help determine the success of the hybridizations. The
Affymetrix Expression Analysis algorithm uses the Tukey’s
biweight estimator to provide a robust mean Signal value
and the Wilcoxon’s rank test to calculate a significance or
p-value and Detection call (present, marginal or absent)
for each probe set. The Detection p-value is calculated
using a Discrimination Score [R] for all probes. The Dis-
crimination Score is a basic property of a probe pair that
describes its ability to detect its intended target. It mea-
sures the target-specific intensity differences of the probe
pair (perfect match (PM) – mismatch (MM)) relative to
Fig. 1 Overall functional analysis. Analysis of the top 15 molecular and cellular functions determined by IPA for the TBI-I (ipsilateral vs. naïve) dataset
(a) and the TBI-C (contralateral vs. naïve) dataset (b) showed that cell death and survival was a top ranked function on both sides of the brain
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its overall hybridization intensity (PM+MM). Background
estimation is provided by a weighted average of the lowest
2 % of the feature intensities. Mismatch probes are utilized
to adjust the perfect match (PM) intensity. Linear scaling
of the feature level intensity values, using the trimmed
mean, is the default to make the means equal for all arrays
being analyzed. False-negative and false-positive rates are
minimized by subtracting nonspecific signal from the PM
probe intensities and performing an intensity-dependent
normalization at the probe set level. Three chips were used
for each experimental group: ipsilateral, contralateral and
naïve control. The dataset produced by the Affymetrix
software contains gene identifiers, corresponding expres-
sion values, and determination of whether genes are con-
firmed as present, marginal or absent. Previous principle
component analysis of the raw datasets demonstrated that
ipsilateral, contralateral and naïve clustered together by in-
jury status and each group was well isolated from the other
two groups [12]. The data were analyzed in Microsoft
Excel for calculation of fold change and whether the genes
were confirmed as present in the tissue sample. Genes in
the injured brain that increased or decreased in expression
by 2-fold or more compared to controls and were present
in either all 3 ipsilateral samples or all 3 contralateral sam-
ples were identified. The gene datasets that were generated
were ipsilateral vs. naïve (TBI-I) and contralateral vs. naïve
(TBI-C) fold changes.
Ingenuity pathway analysis
The gene datasets were analyzed between December 3,
2014 and January 8, 2015 using Ingenuity Pathway Analysis
(Ingenuity® Systems, www.ingenuity.com) and overlaid
onto a global molecular network developed from informa-
tion contained in the Ingenuity Knowledge Base. The
right-tailed Fisher’s Exact Test was used to determine the
likelihood that the association between a set of experimen-
tal genes and a given biological function or pathway is not
due to random chance [19]. In general, p-values less than
0.05 indicate a statistically significant, non-random
association. The functions, canonical pathways, and gene
networks that were most significant to the dataset were
identified. Gene expression profiles were overlaid on the
canonical pathway and gene network figures to reveal
similarities and dissimilarities in their gene expression pat-
terns. Gene networks were also created using Ingenuity
Knowledge Base to further understand specific interactions
between our genes of interest.
TBI-I/TBI-C ratio
We used the following formulas to calculate the ratio
of TBI-I to TBI-C fold changes: (1) Gene increased on
both sides (TBI-I > TBI-C): ratio = (TBI-I)/(TBI-C); (2)
Gene decreased on both sides (TBI-I > TBI-C): ratio =
1/[(TBI-I)/(TBI-C)]; (3) Gene decreased on both sides
(TBI-I < TBI-C): ratio = −1/[(TBI-C)/(TBI-I)]; (4) Gene
Fig. 2 Fluoro-Jade® B staining of the cortex and hippocampus. Fluoro-Jade® B (FJB) staining showed a dense distribution of damaged neurons
throughout all layers of the cortex near the sight of impact (a, b). Damaged neurons were also detected in the hippocampus ipsilateral to the injury
(d). These neurons were sparsely distributed in the hippocampal CA regions. No FJB staining was detected in either brain region contralateral to the
injury (C: cortex; E: hippocampus). FJB: green; Scale bars: 200 μm (a, c-e), 100 μm (b)
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Fig. 3 TUNEL staining of the cortex and hippocampus. TUNEL staining showed distribution of injured cells in the cortex similar to FJB as they
were distributed throughout all layers of the cortex (a, b). However, no TUNEL staining was detected in the ipsilateral hippocampus (d). No
TUNEL was observed on the contralateral side of the brain (C: cortex; E: hippocampus). TUNEL: red; Scale bars: 200 μm (a, c-e), 100 μm (b)
Fig. 4 Breakdown of CD genes based on increased and decreased expression. a 361 CD genes changed uniquely on the ipsilateral side of the
brain and 88 % (317 genes) of those increased in expression. b 136 CD genes changed uniquely on the contralateral side of the brain and 75 %
(102 genes) of those decreased in expression. c There were 405 genes that changed more than 2-fold on both sides of the brain. Eighty-two
percent of them (332 genes) changed similarly while the remaining 18 % (73 genes) changed differently (TBI-I/TBI-C ratio >2; see text)
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Table 1 Genes that change differently on each side of the brain
Gene
symbol








SPP1 secreted phosphoprotein 1 37.905 2.370 15.994 cytokine
TIMP1 TIMP metallopeptidase inhibitor 1 38.486 2.101 18.318 cytokine
CP ceruloplasmin (ferroxidase) 27.838 8.477 3.284 enzyme
FGL2 fibrinogen-like 2 16.793 4.017 4.180 peptidase
LCN2 lipocalin 2 71.824 3.895 18.440 transporter
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 3
58.488 2.509 23.311 other
Plasma Membrane
CD44 CD44 molecule (Indian blood group) 15.558 2.399 6.485 enzyme
EHD4 EH-domain containing 4 2.361 −2.056 4.854 enzyme
SDC1 syndecan 1 13.681 2.566 5.332 enzyme
KCND2 potassium voltage-gated channel, Shal-related subfamily,
member 2
−2.792 −7.585 2.717 ion channel
KCNN4 potassium intermediate/small conductance
calcium-activated channel, subfamily N, member 4
3.088 −9.429 29.117 ion channel
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 −11.813 −23.824 2.017 kinase
EGFR epidermal growth factor receptor 6.773 2.374 2.853 kinase
PTPRF protein tyrosine phosphatase, receptor type, F −6.365 −20.492 3.219 phosphatase
IL6ST interleukin 6 signal transducer 2.307 −3.283 7.574 transmembrane receptor
CD68 CD68 molecule 4.365 2.007 2.175 other
HLA-A major histocompatibility complex, class I, A 9.296 3.657 2.542 other
PMEPA1 prostate transmembrane protein, androgen induced 1 2.682 −2.937 7.877 other
Cytoplasm
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 10.998 4.808 2.287 enzyme
KIF3A kinesin family member 3A −5.083 −11.754 2.312 enzyme
MX1 MX dynamin-like GTPase 1 28.177 7.326 3.846 enzyme
PDE4B phosphodiesterase 4B, cAMP-specific 5.602 2.359 2.375 enzyme
RND3 Rho family GTPase 3 2.864 −2.971 8.509 enzyme
SRXN1 sulfiredoxin 1 6.306 2.402 2.625 enzyme
CARD11 caspase recruitment domain family, member 11 7.343 2.892 2.539 kinase
CSNK2A1 casein kinase 2, alpha 1 polypeptide 2.992 −2.750 8.228 kinase
EIF5B eukaryotic translation initiation factor 5B −3.044 −8.766 2.880 translation regulator
RASA1 RAS p21 protein activator (GTPase activating protein) 1 2.392 −2.105 5.035 transporter
AHI1 Abelson helper integration site 1 2.243 −2.897 6.498 other
CISD2 CDGSH iron sulfur domain 2 −7.833 −19.012 2.427 other
CMIP c-Maf inducing protein −3.778 −13.763 3.643 other
Ctdspl CTD (carboxy-terminal domain, RNA polymerase II,
polypeptide A) small phosphatase-like
−7.271 −36.886 5.073 other
HSPB1 heat shock 27 kDa protein 1 46.922 2.639 17.780 other
KIFAP3 kinesin-associated protein 3 −2.281 −7.831 3.433 other
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 6.082 2.799 2.173 other
LSP1 lymphocyte-specific protein 1 11.716 2.140 5.475 other
PHLDA1 pleckstrin homology-like domain, family A, member 1 5.129 2.160 2.375 other
RDX radixin 4.828 −5.274 25.463 other
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increased ipsilaterally and decreased contralaterally:
ratio = (TBI-I)/-[1/(TBI-C)]; (5) Gene decreased ipsi-
laterally and increased contralaterally: ratio = (TBI-C)/
[1/(TBI-I)].
Histology
At 24 h post injury, rats were anesthetized with an intra-
peritoneal injection of a ketamine:xylazine:acetylproma-
zine cocktail (50:10:1.67 mg/kg respectively) and perfused
Table 1 Genes that change differently on each side of the brain (Continued)
Slpi secretory leukocyte peptidase inhibitor 82.908 3.119 26.582 other
Tpm3 tropomyosin 3 2.592 −2.715 7.037 other
TRIM54 tripartite motif containing 54 −4.426 −2.032 −2.178 other
Nucleus
SETD8 SET domain containing (lysine methyltransferase) 8 2.029 −3.930 7.974 enzyme
TOP2A topoisomerase (DNA) II alpha 170 kDa 2.260 −2.406 5.438 enzyme
CDK11A cyclin-dependent kinase 11A −4.290 −14.872 3.467 kinase
GSK3B glycogen synthase kinase 3 beta −2.733 −6.635 2.428 kinase
SRPK2 SRSF protein kinase 2 −5.614 −23.589 4.202 kinase
THRA thyroid hormone receptor, alpha −2.799 −11.518 4.115 ligand-dependent nuclear
receptor
ATRX alpha thalassemia/mental retardation syndrome X-linked 2.091 −5.964 12.471 transcription regulator
BTG2 BTG family, member 2 −2.220 −5.803 2.614 transcription regulator
CCAR1 cell division cycle and apoptosis regulator 1 −2.943 −11.648 3.958 transcription regulator
CCND1 cyclin D1 2.152 −2.027 4.362 transcription regulator
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 11.271 2.037 5.533 transcription regulator
DEK DEK proto-oncogene −3.006 −7.352 2.446 transcription regulator
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 −4.383 5.614 −24.606 transcription regulator
KLF13 Kruppel-like factor 13 −2.006 −4.582 2.284 transcription regulator
KLF6 Kruppel-like factor 6 6.003 2.865 2.095 transcription regulator
NAA15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit 3.605 −3.751 13.522 transcription regulator
NFIX nuclear factor I/X (CCAAT-binding transcription factor) −2.548 −8.112 3.184 transcription regulator
PA2G4 proliferation-associated 2G4, 38 kDa −2.702 −5.783 2.140 transcription regulator
SMARCA4 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 4
2.521 −7.712 19.442 transcription regulator
STAT3 signal transducer and activator of transcription 3
(acute-phase response factor)
4.219 −3.771 15.910 transcription regulator
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 2.587 −2.134 5.521 transcription regulator
TCF4 transcription factor 4 −2.216 −4.625 2.087 transcription regulator
TPR translocated promoter region, nuclear basket protein 2.212 −2.728 6.034 transporter
Brd4 bromodomain containing 4 −3.528 −15.202 4.309 other
CDT1 chromatin licensing and DNA replication factor 1 3.098 −2.295 7.110 other
GADD45G growth arrest and DNA-damage-inducible, gamma 3.191 −2.384 7.607 other
PSIP1 PC4 and SFRS1 interacting protein 1 −2.663 2.113 −5.627 other
Rbm25 RNA binding motif protein 25 −5.547 −16.213 2.923 other
THOC2 THO complex 2 2.119 −4.886 10.353 other
Unknown
EIF3C eukaryotic translation initiation factor 3, subunit C −4.369 −9.072 2.076 translation regulator
Nos1ap nitric oxide synthase 1 (neuronal) adaptor protein −2.698 −5.717 2.119 other
RASSF4 Ras association (RalGDS/AF-6) domain family member 4 4.289 2.106 2.037 other
TBI-I/TBI-C Ratio: Gene increased on both sides (TBI-I > TBI-C): ratio = (TBI-I)/(TBI-C); Gene decreased on both sides (TBI-I > TBI-C): ratio = 1/[(TBI-I)/(TBI-C)]; Gene
decreased on both sides (TBI-I < TBI-C): ratio = −1/[(TBI-C)/(TBI-I)]; Gene increased ipsilaterally and decreased contralaterally: ratio = (TBI-I)/-[1/(TBI-C)]; Gene
decreased ipsilaterally and increased contralaterally: ratio = (TBI-C)/[1/(TBI-I)]
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transcardially with saline followed by cold 4 % paraformal-
dehyde solution in PBS for 30 min. Brains were quickly
removed and cryoprotected in 30 % sucrose. The brains
were then frozen in OCT mounting medium and stored
until sectioning. Coronal sections of 20 μm thickness were
cryosectioned from the perilesional brain area of each ani-
mal. Sections were mounted on slides which were stored at
−80 °C until further processed. Fluoro-Jade® B (AG310,
Millipore, Billerica, MA) labeling was performed as previ-
ously described [20]. TUNEL staining was performed using
the TUNEL reaction mixture from the In Situ Cell Death
Detection Kit, TMR red (12 156 792 910, Roche Diagnos-
tics, Mannheim, Germany). Briefly, slide-mounted sections
were post-fixed with 4 % paraformaldehyde for 15 min
followed by a 10 min incubation in a 20 μg/mL proteinase
K solution in 100 mM Tris HCl (pH 8.0) and 50 mM
EDTA. The sections were then incubated for 60 min at 37 °
C in the TUNEL reaction mixture. Phosphate buffered sa-
line was used to rinse the sections after each step. A Zeiss
fluorescence microscope equipped with a CCD camera
(Carl Zeiss Microimaging, Inc., Thornwood, NY) was used
to capture digital images of the sections.
Real-time polymerase chain reaction (PCR)
RNA was extracted as above and quantified using the
Nanodrop 2000c (Thermo Scientific, Waltham, MA).
Equal amounts of ipsilateral, contralateral, and naïve
RNA (n = 2 for each) were converted to cDNA using the
iScript™ Reverse Transcription Supermix for RT-qPCR
(170–8840, Bio-Rad Laboratories, Inc., Hercules, CA).
The resulting product was diluted 1:100 with RNase-
free sterile water. The diluted product was used in the
real-time PCR analysis using the Quantitect SYBR®
Green PCR Kit (204143, Qiagen, Hilden, Germany), cus-
tom oligo primers for SPP1, HSPB1, STAT3, CCND1, and
GAPDH (reference gene) (Life Technologies, Rockville,
MD), and a Bio-Rad CFX96™ Real-Time System mounted
on a C1000™ Thermal Cycler. All steps were carried out
according to manufacturer’s protocols. The real-time PCR
results were analyzed using the ΔΔCt method where
ΔCt1 = Ct (Target A‐exp) – Ct (GAPDH-exp); ΔCt2 = Ct
(Target A‐naïve) –Ct (GAPDH‐naïve); and ΔΔCt =ΔCt1 –
ΔCt2. The normalized target gene expression level was
given by 2-ΔΔCt. The results were compared pairwise using
a one-tail T-test assuming equal variance. Differences were
considered significant when p < 0.05.
Results
Functional analysis
To begin understanding the cell death gene response
following TBI, we first looked at the biological func-
tions associated with our datasets. Analysis of the top
Fig. 5 Canonical pathway analysis. The apoptosis signaling pathway with all gene families, groups and complexes expanded to show the member genes
and showing the relative expression values of potential GOI for TBI-I (a) and TBI-C (b) included in this pathway. red: relative increase in expression; green: relative
decrease in expression; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original pathway
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15 molecular and cellular functions associated with the
TBI-I (ipsilateral vs. naïve) and TBI-C (contralateral vs.
naïve) datasets in IPA showed that cell death and
survival (CD) was the second ranked TBI-I function
that is also ranked in the top 7 functions for TBI-C
(Fig. 1a, b). Also ranked in the top 7 molecular and cel-
lular functions for both datasets are cellular growth
and proliferation, cellular assembly and organization,
cellular function and maintenance, cellular develop-
ment, and cell morphology. Cellular movement and
cell-to-cell signaling and interaction are ranked in the
top 7 only for TBI-I and TBI-C, respectively.
Histology
To examine cell death histologically, we chose to look at
the cortical area adjacent to the impact site so we could ob-
serve the cellular response to the injury in all layers of the
cortex. This is not possible at the impact site because of the
resulting injury cavity. Fluoro-Jade® B (FJB) staining showed
a dense distribution of damaged neurons throughout all
layers of the cortex near the sight of impact (Fig. 2a, b).
Damaged neurons were also detected in the hippocampus
ipsilateral to the injury (Fig. 2d). These neurons were
sparsely distributed in the hippocampal CA regions. No FJB
staining was detected in the cortex (Fig. 2c) or hippocam-
pus (Fig. 2e) contralateral to the injury.
TUNEL staining showed distribution of injured cells in
the cortex similar to FJB as they were distributed through-
out all layers of the cortex (Fig. 3a, b). However, no TUNEL
staining was detected in the ipsilateral hippocampus (Fig. 3d),
suggesting that the neuronal damage in that region had not
yet progressed to apoptosis. No TUNEL was observed in
the contralateral cortex (Fig. 3c) or hippocampus (Fig. 3e).
Cell death gene expression patterns
Focusing on the CD genes in our datasets, we deter-
mined that 902 CD genes had a greater than 2-fold
change in expression. Of these genes, 361 CD genes
changed uniquely on the ipsilateral side of the brain.
317 of those genes (88 %) increased while 44 genes
(12 %) decreased in expression (Fig. 4a). 136 CD genes
changed uniquely on the contralateral side of the brain
and, in contrast to what we observed on the ipsilateral
side, only 34 genes (25 %) increased while 102 genes
(75 %) decreased in expression (Fig. 4b).
There were 405 CD genes that changed on both the ipsi-
lateral and contralateral sides of the brain. In order to
determine whether these common genes changed differ-
ently on one side of the brain compared to the other, we
Table 2 The top 6 gene networks associated with the TBI-I dataset
Network
ID
Molecules in network Score Focus
molecules
Top diseases and functions
1 CADM1, CALB1, CBFB, CDCA7L, CMIP, Cytochrome bc1,
cytochrome-c oxidase, DAB2, DEDD, FGF9, FLNA, FYN, GCLC,
GCLM, GFAP, GFRA1, ITGA6, JDP2, MAOA, MED14, MGEA5,
NFE2L1, NFE2L2, NPTX1, NRP1, PDHA1, PDLIM7, RET, Rnr,
RPS24, RTN4, SLC18A2, Sos, STK17B, TAF4B
46 31 Cell Death and Survival, Drug Metabolism,
Molecular Transport
2 AMOT, ANXA1, API5, ATF3, ATG12, BAG3, CCNA2, Cdc2, CDK1,
CDK2, CDKN1B, ETV5, FGFR3, FN1, GJA1, Hedgehog, LATS1, MCL1,
MCM2, MCM8, MLLT4, MMS22L, NAA15, Patched, PIK3C2A, PKP2,
PSMA7, RAB35, RPRM, SPIN1, TAGLN2, THOC2, TJP2, UNC5B, XPO1
46 32 Cell Death and Survival, Cell Cycle,
Reproductive System Development
and Function
3 AHCTF1, AKAP12, amylase, BCL11A, CA4, CACNA1G, CCND1,
CLCN7, CREB1, CREBBP, CSF1, CSRNP1, CTNNB1, DES, Histone h3,
IKK (complex), ITPR2, KLF6, KPNB1, MITF, MTMR1, NFIX, PRKD3,
PTGR1, RAI14, RNA polymerase II, RRM2, SENP2, SMAD4, SMARCA4,
SUDS3, TBL1XR1, TGM2, THRA, ZBTB18
43 31 Cell Death and Survival, Organismal
Survival, Gene Expression
4 ABCA1, ALB, ALDH1A2, BTG2, Ccl2, Ccl7, CD36, CEBPB, chemokine,
CREM, CXCL3, DUSP5, EGR2, FGF2, FGL2, FOSL1, FSH, Hmgb2
(includes others), HMOX1, IL1, IL12 (family), IL6R, ITGB2, KLF4, MAPK9,
NEK6, NEK7, PDE4B, Pld, PRKCI, PTGS2, SPP1, THBD, TLR4, WNT5A
42 30 Cellular Movement, Hematological System
Development and Function, Immune Cell
Trafficking
5 ACSL5, AGTR2, AMFR, AVP, CAMK2N1, CAPRIN1, CHSY1, CUL5, DCK,
ELAVL1, Endothelin, GMCL1, GNRH, Insulin, MAP4K4, MSI2, MTORC1,
NEO1, OPA1, Proinsulin, PTGER3, Relaxin, RNF2, SLC2A3, SMAD7,
STAG1, TACR1, TCEB3, TMEM123, TRAF6, WAPAL, WFS1, WTAP,
ZMYM2, ZNF280B
41 29 Cell Death and Survival, Cardiovascular
System Development and Function,
Hereditary Disorder
6 26 s Proteasome, ARL11, BCL2L1, CAMK1G, CAMK2D, CASP3, CAV1,
CISD2, CLASP1, CLN5, DLG4, EN2, ENC1, Esr1-Esr1-estrogen-estrogen,
FBXO9, G2E3, Hsp70, Hsp90, HSP90AB1, IDE, KIF1B, MDM2, PCDH15,
PGR, PI4K2A, PRDM2, PSEN1, SGPL1, SNCA, SPTBN1, SRC (family),
SRPK2, TMEM109, TRIM2, VPS41
40 30 Cell Death and Survival, Cancer,
Neurological Disease
Bold= > Gene included in the dataset
Note: Some of the nodes in the original networks represent gene groups, complexes or families that, when expanded, contain more potential GOI
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Table 3 The top 6 gene networks associated with the TBI-C dataset
Network
ID
Molecules in network Score Focus
molecules
Top diseases and functions
1 ACER2, ACIN1, ACVR1C, ALDH1A2, ARHGEF7, BCL11B, caspase, CBFB,
CD38, CD44, CLCN3, CUL5, DPYD, EEF1A2, FGL2, Fibrinogen, ITGB1,
MAP3K1, MAP3K8, MAPK8, MAPK9, MIF, MTDH, PAK1, PRDX6, Rac,
RAD23B, SPARC, Srebp, TNKS2, TTLL1, VCL, WNT5A, ZBTB18, ZYX
50 31 Cell Death and Survival, Cellular
Movement, Ophthalmic Disease
2 ABCA1, AURKAIP1, BRINP1, BTG2, CACNA1G, CAV1, CCND1, CDK2,
DCK, GCLC, Histone h3, Histone h4, Insulin, IRAK1, KMT2A, LCN2, MAFG,
MTMR1, P110, PIAS1, PPARGC1B, Pro-inflammatory Cytokine, Ras homolog,
RBM5, RNA polymerase II, SBF1, SETD8, SLC18A2, SMARCA2, SOX2,
STAT1, TRPM7, ZBTB7A, ZMYND11, ZNF148
44 28 Cell Death and Survival, Gene Expression,
Cellular Growth and Proliferation
3 ADNP, AHI1, ANKS1B, ARL6IP1, CDK11A, CXCL12, DNAJB6, ENC1,
estrogen receptor, FBXO9, FBXW7, FGFR3, G2E3, Hdac, HSP, Hsp90,
HSP90AA1, HSP90AB1, HSPB1, KLF9, KLF13, LINGO1, MED1, MED14,
mediator, PA2G4, PGR, PPP3CB, RNF4, STUB1, THRA, TRAP/Media,
TUFM, Ubiquitin, VPS41
43 28 Cell Death and Survival, Post-Translational
Modification, Protein Folding
4 A2M, ACACA, AKT2, ALDH1A1, Alp, AMPK, ATG12, ATP1A1, BSG, CA3,
EIF5B, ENTPD5, FGF9, FGFR1, Focal adhesion kinase, FOXO1, KRAS,
MAP1B, MEF2A, Mlc, NLK, NTRK3, PALLD, PDPK1, PITX2, PPP3R1,
PRKAA1, PRKCD, PSMA7, RASSF4, RPS24, Serbp1, Sfk, STK17B, TAOK1
41 30 Cell Death and Survival, Carbohydrate
Metabolism, Cellular Development
5 ACAC, AP2B1, APAF1, APC-AXIN-GSK3β, ATP2A2, ATP2B1, ATP2B2, BAX,
Ca2 ATPase, calpain, CAST, CDH13, Cytochrome bc1, cytochrome C,
cytochrome-c oxidase, DDIT4, DNM1L, GBX2, glutathione peroxidase,
GSK3B, ITSN1, KCND2, LMO4, MAFB, MAOA, MFN1, Mitochondrial com-
plex 1, MTF2, NCS1, NDUFAB1, NFE2L1, OPA1, PACS2, PEX11B, PRKAA2
39 26 Cell Death and Survival, Cell Cycle,
Cellular Compromise
6 Ap1, ARHGAP1, ARL6IP5, CCDC86, CCND2, CEBPD, Cg, COL1A1,
DACH1, FSH, Growth hormone, Gsk3, IGFBP3, Lh, MGEA5, NEO1, PDHA1,
PPP2R1A, PRLR, PSIP1, PURA, RAB27A, RPRM, RSF1, SMAD4, SMAD7,
Smad1/5/8, Smad2/3, SP1, SPP1, TAF4B, Tgf beta, TIMP1, TNRC6A, ZMYM2
39 26 Cell Death and Survival, Tissue
Development, Cellular Growth
and Proliferation
Bold= > Gene included in the dataset
Note: Some of the nodes in the original networks represent gene groups, complexes or families that, when expanded, contain more potential GOI
Fig. 6 Examples of TBI-I networks. TBI-I CD networks 2 (a) and 4 (b) (see Table 2) with all gene families, groups and complexes expanded to show the
member genes and showing the relative expression values of potential GOI for TBI-I. red: relative increase in expression; green: relative decrease in expres-
sion; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original network
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calculated the ratio of the TBI-I fold change to the TBI-C
fold change. Those genes that had a TBI-I/TBI-C ratio
greater than 2 were determined to have changed differently.
We observed that 332 of the common CD genes (82 %)
changed similarly (TBI-I/TBI-C ratio < 2; Fig. 4c). Of the
genes that changed similarly, 242 genes (60 %) increased in
expression and 90 genes (22 %) decreased in expression.
The remaining 73 common CD genes (18 %) changed dif-
ferently (TBI-I/TBI-C ratio > 2) (Fig. 4c). Table 1 shows the
73 common CD genes that changed differently. These
genes span all cellular compartments (extracellular space,
plasma membrane, cytoplasm, and nucleus) with diverse
molecule types. The expression of all these genes was lower
on the contralateral side of the brain with the exception
of 3 genes, DNAJB6, TRIM54 and PSIP1 (negative
TBI-I/TBI-C ratio). Because of their different expres-
sion patterns, these 73 genes became our first group
of genes of interest (GOI; Table 1). Notable genes
given their high TBI-I/TBI-C ratio included SPP1, TIMP1,
LCN2, SERPINA3, KCNN4, HSPB1, RDX, Slpi, ATRX,
DNAJB6, NAA15, SMARCA4, STAT3, and THOC2.
Canonical pathway analysis
We used canonical pathway and network analysis in IPA to
identify genes in our datasets that were potentially most
relevant to the observed CD gene response. We defined
Fig. 7 Examples of TBI-C networks. TBI-C CD networks 2 (a) and 4 (b) (see Table 3) with all gene families, groups and complexes expanded to show the
member genes and showing the relative expression values of potential GOI for TBI-C. red: relative increase in expression; green: relative decrease in expression;
white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original network
Table 4 Identification of genes of interest from TBI-I network analysis
Network
ID







1 CALB1, CDCA7L, CMIP, DAB2, FLNA, GCLM, GFAP, NFE2L2,
PDLIM7
9 1 8 undefined
2 ANXA1, ATF3, BAG3, CCNA2, CDK1, CDKN1B, ETV5, FN1, LATS1,
MCL1, MCM2, MCM8, MMS22L, NAA15, RAB35, SPIN1, TAGLN2,
THOC2, TJP2, UNC5B
20 4 16 undefined, enzymes, and
kinases
3 BCL11A, CCND1, CREB1, CREBBP, CSRNP1, DES, IKBKB, ITPR2, KLF6,
KPNB1, MITF, NFIX, PTGR1, RAI14, RRM2, SENP2, SMARCA4, SUDS3,
TBL1XR1, TGM2, THRA
21 7 14 transcription regulators and
enzymes
4 ALB, BTG2, Ccl2, CCL3L3, CCL4, Ccl6, Ccl7, CD36, CEBPB, CREM,
CX3CL1, CXCL3, Cxcl9, DUSP5, EGR2, FGF2, FGL2, FOSL1, HMOX1,
IL1B, IL6R, ITGB2, KLF4, NEK6, PDE4B, PTGS2, SPP1, TLR4
28 4 24 cytokines, transcription
regulators, and
transmembrane receptors
5 ACSL5, CAMK2N1, CHSY1, ELAVL1, MAP4K4, MSI2, PTGER3, TCEB3,
TMEM123, TRAF6, WFS1
11 2 9 undefined and kinases
6 ARL11, CAMK1G, CASP3, CISD2, CLN5, DNAJB6, DNAJB9, FGR, HCK,
HSPA1A/HSPA1B, HSPA2, HSPA9, HSPB8, MDM2, PCDH15,
PI4K2A, PRDM2, SGPL1, SNCA, SRPK2, TMEM109
21 4 17 undefined, kinases, and
transcription regulators
Italics= > gene of interest also found in a previous analysis; Bold= > GOI unique to this analysis
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potential GOI, in this context, as those genes that either
changed in expression uniquely on one side of the brain, or
were one of the 73 common genes that changed differently
(Table 1). GOI were identified by comparing the genes in
the canonical pathway and gene networks to the list of
unique TBI-I or TBI-C CD genes with the genes from
Table 1 added to each list and identifying the overlapping
genes. Canonical pathways in IPA are well-characterized
metabolic and cell signaling pathways derived from infor-
mation found in specific journal articles, review articles,
text books, and KEGG Ligand [21]. Fig. 5 shows the apop-
tosis signaling canonical pathway with all relevant gene
families, groups and complexes expanded to show the
member genes. This pathway was chosen because
apoptosis is a key process in cell death following TBI
[22–24]. By overlaying the relative expression values
of potential GOI for TBI-I (Fig. 5a) and TBI-C
(Fig. 5b), we were able to identify 9 GOI that were
increased (BCL2A1 (Bfl-1 in pathway), CASP3,
CASP7, CDK1 (Cdc2), IKBKB, MAP4K4, MCL1,
NFKB2, and TNFRSF1A) in the TBI-I dataset, 3 GOI
that decreased (ACIN1 (Acinus), BAX and KRAS)
and 1 GOI that increased (MAPK8 (JNK1)) in the
TBI-C dataset.
Gene network analysis
In contrast to canonical pathways, which are relatively im-
mutable in IPA, gene networks are generated de novo in
IPA based on the list of genes that are imported. IPA takes
“seed” molecules from the gene list, searches the Ingenuity
Knowledge Base, and uses a network algorithm to draw
connections between molecules based on biological func-
tion [25]. In order to generate the networks, we performed
an IPA core analysis on the TBI-I and TBI-C CD datasets.
IPA scores the networks in order to rank them according
to their degree of relevance to the network eligible mole-
cules in the dataset [25]. The top 6 scoring networks for
each dataset were used to identify GOI.
Five of the top 6 networks for TBI-I and all 6 networks
for TBI-C have cell death and survival as their top associ-
ated biological function (Tables 2 and 3). Only TBI-I
network 4 does not have cell death and survival as one of
the top 3 associated biological functions. Figure 6 shows
networks 2 and 4 (Table 2) as examples of the TBI-I
analysis. Figure 7 shows networks 2 and 4 (Table 3) as
examples of the TBI-C analysis. (The other networks are
available as supplemental materials (Additional files 1
and 2).) Like the canonical pathway analysis, all rele-
vant gene families, groups and complexes were ex-
panded to show the member genes. The relative TBI-I
(Fig. 6) and TBI-C (Fig. 7) gene expression values of
potential GOI were overlaid on these networks and
additional GOI were identified. Tables 4 and 5 show the
resulting GOI that were identified through this analysis.
For TBI-I, a total of 110 GOI were found in these
networks, 22 of which were previously identified (Table 4).
Thus, 88 additional GOI were identified for TBI-I. For
TBI-C, 38 additional GOI were identified as 28 of the 66
GOI found had been previously identified (Table 5). The
most prevalent molecular types for TBI-I were tran-
scription regulators, unspecified enzymes, kinases, and
undefined molecules. Kinases transcription regulators,
unspecified enzymes, and undefined molecules were
most prevalent in the TBI-C analysis.
Compiling the gene interaction hierarchy (GIH)
TBI-I: By combining the GOI identified through canon-
ical pathway and network analysis with those in Table 1,
we identified a total of 170 GOI. In order to determine
which genes might be most relevant to CD, we ranked
these genes relative to each other by the number of
direct interactions each had with the other GOI. Our
analysis showed that 145 of the GOI formed an inter-
connected network, leaving 25 “orphan” genes (see
Additional file 3). Genes having 1st order connections
with more than 10 % of the other genes within the main
Table 5 Identification of genes of interest from TBI-C network analysis
Network
ID







1 ACIN1, ACVR1C, CD44, DPYD, FGL2, MAPK8, MTDH, RAD23B,
TTLL1
9 4 5 enzymes and kinases
2 AURKAIP1, BTG2, CCND1, LCN2, MAFG, PIK3CD, PIK3R2,
RND3, SETD8, SOX2, TRPM7, ZMYND11, ZNF148
13 5 8 transcription regulators, kinases,
and enzymes
3 AHI1, CDK11A, CDK19, DNAJB6, HSP90AA1, HSPB1, KLF13,
LINGO1, MED1, PA2G4, PPP3CB, THRA, TUFM
13 7 6 transcription regulators,
undefined, and kinases
4 EIF5B, ENTPD5, FOXO1, KRAS, MEF2A, PALLD, PRKAA2,
PTK2B, RASSF4, Serbp
10 3 7 undefined, transcription
regulators, enzymes, and kinases
5 ATP2A2, ATP2B2, BAX, CDH13, GBX2, GSK3B, KCND2, MAFB,
MFN1, NDUFAB1, PRKAA2
11 4 7 transporters, kinases, enzymes,
and undefined
6 CCDC86, CCND2, CEBPD, GSK3B, PRLR, PSIP1, RSF1, SP1, SPP1,
TIMP1
10 5 5 transcription regulators,
undefined, and cytokines
Italics= > gene of interest also found in a previous analysis; Bold= > GOI unique to this analysis
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GOI network (>14 connections) were considered “pri-
mary” in this analysis (see Fig. 8 for an example). Genes
having connections with 5 %–10 % of the other genes
(8–14 connections) were considered “secondary” (see
Additional file 4 for an example) and those with connec-
tions with less than 5 % of the other genes (<8 connec-
tions) were considered “peripheral”. The resultant GIH
is displayed in Table 6.
Fig. 8 An example of calculating the number of direct connections for the TBI-I GOI network. In IPA, the gene in question was selected (MDM2
in this example). Then, its direct connections were selected by right clicking on MDM2 and using the “select nearest neighbors” option (highlighted in
purple). A list of the selected genes was exported and MDM2 was removed from the list (upper right corner). The remaining genes were counted
(26 in this example) and MDM2 was ranked in the TBI-I gene interaction hierarchy (primary tier) by this number
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Table 6 TBI-I Gene interaction hierarchy (GIH)






ATF3 activating transcription factor 3 12.027 Nucleus transcription regulator
CCND1 cyclin D1 2.152 Nucleus transcription regulator
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 3.366 Nucleus transcription regulator
CREB1 cAMP responsive element binding protein 1 2.666 Nucleus transcription regulator
CREBBP CREB binding protein 2.421 Nucleus transcription regulator
MDM2 MDM2 proto-oncogene, E3 ubiquitin protein ligase 2.01 Nucleus transcription regulator
NFE2L2 nuclear factor, erythroid 2-like 2 2.452 Nucleus transcription regulator
SMARCA4 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 4
2.521 Nucleus transcription regulator
STAT3 signal transducer and activator of transcription 3
(acute-phase response factor)
4.219 Nucleus transcription regulator
CDK1 cyclin-dependent kinase 1 2.105 Nucleus kinase
CSNK2A1 casein kinase 2, alpha 1 polypeptide 2.992 Cytoplasm kinase
EGFR epidermal growth factor receptor 6.773 Plasma Membrane kinase
GSK3B glycogen synthase kinase 3 beta −2.733 Nucleus kinase
CD44 CD44 molecule (Indian blood group) 15.558 Plasma Membrane enzyme
FN1 fibronectin 1 3.97 Extracellular Space enzyme
TRAF6 TNF receptor-associated factor 6, E3 ubiquitin protein ligase 2.163 Cytoplasm enzyme
CASP3 caspase 3, apoptosis-related cysteine peptidase 2.535 Cytoplasm peptidase
ELAVL1 ELAV like RNA binding protein 1 3.275 Cytoplasm other
Secondary
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 11.271 Nucleus transcription regulator
CREM cAMP responsive element modulator 2.165 Nucleus transcription regulator
EGR2 early growth response 2 2.271 Nucleus transcription regulator
FOSL1 FOS-like antigen 1 5.875 Nucleus transcription regulator
KLF4 Kruppel-like factor 4 (gut) 2.057 Nucleus transcription regulator
MITF microphthalmia-associated transcription factor 4.755 Nucleus transcription regulator
TCF4 transcription factor 4 −2.216 Nucleus transcription regulator
HSPA1A/
HSPA1B
heat shock 70 kDa protein 1A 3.137 Cytoplasm enzyme
MCM2 minichromosome maintenance complex component 2 2.57 Nucleus enzyme
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin
G/H synthase and cyclooxygenase)
3.106 Cytoplasm enzyme
IL1B interleukin 1, beta 5.166 Extracellular Space cytokine
SPP1 secreted phosphoprotein 1 37.905 Extracellular Space cytokine
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) 3.732 Nucleus kinase
IKBKB inhibitor of kappa light polypeptide gene enhancer in
B-cells, kinase beta
2.127 Cytoplasm kinase
KPNB1 karyopherin (importin) beta 1 3.173 Nucleus transporter
MCL1 myeloid cell leukemia 1 3.25 Cytoplasm transporter
THRA thyroid hormone receptor, alpha −2.799 Nucleus ligand-dependent nuclear
receptor
CASP7 caspase 7, apoptosis-related cysteine peptidase 2.579 Cytoplasm peptidase
BAG3 BCL2-associated athanogene 3 4.045 Cytoplasm other
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Table 6 TBI-I Gene interaction hierarchy (GIH) (Continued)
CCNA2 cyclin A2 2.633 Nucleus other
GFAP glial fibrillary acidic protein 3.011 Cytoplasm other
HSPA9 heat shock 70 kDa protein 9 (mortalin) 2.666 Cytoplasm other
HSPB1 heat shock 27 kDa protein 1 46.922 Cytoplasm other
SNCA synuclein, alpha (non A4 component of amyloid precursor) −2.169 Cytoplasm other
Peripheral
ACSL5 acyl-CoA synthetase long-chain family member 5 −2.361 Cytoplasm enzyme
ANXA1 annexin A1 3.535 Plasma Membrane enzyme
CHSY1 chondroitin sulfate synthase 1 2.873 Cytoplasm enzyme
CP ceruloplasmin (ferroxidase) 27.838 Extracellular Space enzyme
EHD4 EH-domain containing 4 2.361 Plasma Membrane enzyme
GCLM glutamate-cysteine ligase, modifier subunit 2.019 Cytoplasm enzyme
HMOX1 heme oxygenase (decycling) 1 9.778 Cytoplasm enzyme
MCM8 minichromosome maintenance complex component 8 2.027 Nucleus enzyme
MX1 MX dynamin-like GTPase 1 28.177 Cytoplasm enzyme
PDE4B phosphodiesterase 4B, cAMP-specific 5.602 Cytoplasm enzyme
RAB35 RAB35, member RAS oncogene family 2.086 Cytoplasm enzyme
RRM2 ribonucleotide reductase M2 3.34 Nucleus enzyme
SDC1 syndecan 1 13.681 Plasma Membrane enzyme
SETD8 SET domain containing (lysine methyltransferase) 8 2.029 Nucleus enzyme
SGPL1 sphingosine-1-phosphate lyase 1 3.108 Cytoplasm enzyme
SRXN1 sulfiredoxin 1 6.306 Cytoplasm enzyme
TGM2 transglutaminase 2 3.574 Cytoplasm enzyme
TOP2A topoisomerase (DNA) II alpha 170 kDa 2.26 Nucleus enzyme
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) −2.38 Nucleus transcription regulator
BTG2 BTG family, member 2 −2.22 Nucleus transcription regulator
CCAR1 cell division cycle and apoptosis regulator 1 −2.943 Nucleus transcription regulator
CSRNP1 cysteine-serine-rich nuclear protein 1 2.821 Nucleus transcription regulator
DEK DEK proto-oncogene −3.006 Nucleus transcription regulator
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 −4.383 Nucleus transcription regulator
ETV5 ets variant 5 −2.163 Nucleus transcription regulator
KLF13 Kruppel-like factor 13 −2.006 Nucleus transcription regulator
KLF6 Kruppel-like factor 6 6.003 Nucleus transcription regulator
NAA15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit 3.605 Nucleus transcription regulator
NFIX nuclear factor I/X (CCAAT-binding transcription factor) −2.548 Nucleus transcription regulator
NFKB2 nuclear factor of kappa light polypeptide gene enhancer
in B-cells 2 (p49/p100)
2.768 Nucleus transcription regulator
PA2G4 proliferation-associated 2G4, 38 kDa −2.702 Nucleus transcription regulator
PRDM2 PR domain containing 2, with ZNF domain 3.677 Nucleus transcription regulator
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 2.587 Nucleus transcription regulator
TCEB3 transcription elongation factor B (SIII), polypeptide 3
(110 kDa, elongin A)
3.053 Nucleus transcription regulator
CAMK1G calcium/calmodulin-dependent protein kinase IG −2.271 Cytoplasm kinase
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 −11.813 Plasma Membrane kinase
CARD11 caspase recruitment domain family, member 11 7.343 Cytoplasm kinase
CDK11A cyclin-dependent kinase 11A −4.29 Nucleus kinase
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Table 6 TBI-I Gene interaction hierarchy (GIH) (Continued)
FGR FGR proto-oncogene, Src family tyrosine kinase 3.915 Nucleus kinase
HCK HCK proto-oncogene, Src family tyrosine kinase 3.887 Cytoplasm kinase
HSPB8 heat shock 22 kDa protein 8 4.112 Cytoplasm kinase
LATS1 large tumor suppressor kinase 1 2.003 Nucleus kinase
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 2.258 Cytoplasm kinase
NEK6 NIMA-related kinase 6 2.322 Nucleus kinase
SRPK2 SRSF protein kinase 2 −5.614 Nucleus kinase
TJP2 tight junction protein 2 2.552 Plasma Membrane kinase
Ccl2 chemokine (C-C motif) ligand 2 195.455 Extracellular Space cytokine
CCL3L3 chemokine (C-C motif) ligand 3-like 3 5.269 Extracellular Space cytokine
CCL4 chemokine (C-C motif) ligand 4 2.162 Extracellular Space cytokine
Ccl6 chemokine (C-C motif) ligand 6 10.291 Extracellular Space cytokine
Ccl7 chemokine (C-C motif) ligand 7 124.78 Extracellular Space cytokine
CXCL3 chemokine (C-X-C motif) ligand 3 13.211 Extracellular Space cytokine
Cxcl9 chemokine (C-X-C motif) ligand 9 2.846 Extracellular Space cytokine
TIMP1 TIMP metallopeptidase inhibitor 1 38.486 Extracellular Space cytokine
IL6R interleukin 6 receptor 2.315 Plasma Membrane transmembrane receptor
IL6ST interleukin 6 signal transducer 2.307 Plasma Membrane transmembrane receptor
ITGB2 integrin, beta 2 (complement component 3 receptor
3 and 4 subunit)
2.675 Plasma Membrane transmembrane receptor
TLR4 toll-like receptor 4 2.699 Plasma Membrane transmembrane receptor
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 3.555 Plasma Membrane transmembrane receptor
UNC5B unc-5 homolog B (C. elegans) 2.067 Plasma Membrane transmembrane receptor
ALB albumin −3.125 Extracellular Space transporter
LCN2 lipocalin 2 71.824 Extracellular Space transporter
RASA1 RAS p21 protein activator (GTPase activating protein) 1 2.392 Cytoplasm transporter
TPR translocated promoter region, nuclear basket protein 2.212 Nucleus transporter
FGL2 fibrinogen-like 2 16.793 Extracellular Space peptidase
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 2.051 Nucleus peptidase
DUSP5 dual specificity phosphatase 5 3.285 Nucleus phosphatase
PTPRF protein tyrosine phosphatase, receptor type, F −6.365 Plasma Membrane phosphatase
EIF3C eukaryotic translation initiation factor 3, subunit C −4.369 Other translation regulator
EIF5B eukaryotic translation initiation factor 5B −3.044 Cytoplasm translation regulator
FGF2 fibroblast growth factor 2 (basic) 2.387 Extracellular Space growth factor
KCND2 potassium voltage-gated channel, Shal-related subfamily,
member 2
−2.792 Plasma Membrane ion channel
AHI1 Abelson helper integration site 1 2.243 Cytoplasm other
BCL2A1 BCL2-related protein A1 3.055 Cytoplasm other
CALB1 calbindin 1, 28 kDa −2.091 Cytoplasm other
CD68 CD68 molecule 4.365 Plasma Membrane other
CDCA7L cell division cycle associated 7-like 2.648 Nucleus other
CDT1 chromatin licensing and DNA replication factor 1 3.098 Nucleus other
CISD2 CDGSH iron sulfur domain 2 −7.833 Cytoplasm other
CMIP c-Maf inducing protein −3.778 Cytoplasm other
DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2
(Drosophila)
3.053 Plasma Membrane other
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Table 6 TBI-I Gene interaction hierarchy (GIH) (Continued)
DES desmin 2.857 Cytoplasm other
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.128 Nucleus other
FLNA filamin A, alpha 3.45 Cytoplasm other
GADD45G growth arrest and DNA-damage-inducible, gamma 3.191 Nucleus other
HLA-A major histocompatibility complex, class I, A 9.296 Plasma Membrane other
HSPA2 heat shock 70 kDa protein 2 3.51 Cytoplasm other
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 6.082 Cytoplasm other
LSP1 lymphocyte-specific protein 1 11.716 Cytoplasm other
MMS22L MMS22-like, DNA repair protein 2.918 Nucleus other
MSI2 musashi RNA-binding protein 2 2.288 Cytoplasm other
PDLIM7 PDZ and LIM domain 7 (enigma) 4.695 Cytoplasm other
PHLDA1 pleckstrin homology-like domain, family A, member 1 5.129 Cytoplasm other
PMEPA1 prostate transmembrane protein, androgen induced 1 2.682 Plasma Membrane other
PSIP1 PC4 and SFRS1 interacting protein 1 −2.663 Nucleus other
RDX radixin 4.828 Cytoplasm other
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 3
58.488 Extracellular Space other
SPIN1 spindlin 1 2.178 Nucleus other
SUDS3 suppressor of defective silencing 3 homolog (S. cerevisiae) 2.228 Nucleus other
TAGLN2 transgelin 2 3.891 Cytoplasm other
THOC2 THO complex 2 2.119 Nucleus other
TMEM109 transmembrane protein 109 2.106 Cytoplasm other
TMEM123 transmembrane protein 123 2.348 Plasma Membrane other
Orphan
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 10.998 Cytoplasm enzyme
KIF3A kinesin family member 3A −5.083 Cytoplasm enzyme
PTGR1 prostaglandin reductase 1 2.258 Cytoplasm enzyme
RND3 Rho family GTPase 3 2.864 Cytoplasm enzyme
WFS1 Wolfram syndrome 1 (wolframin) 2.083 Cytoplasm enzyme
ITPR2 inositol 1,4,5-trisphosphate receptor, type 2 2.489 Cytoplasm ion channel
KCNN4 potassium intermediate/small conductance calcium-activated
channel, subfamily N, member 4
3.088 Plasma Membrane ion channel
ATRX alpha thalassemia/mental retardation syndrome X-linked 2.091 Nucleus transcription regulator
RAI14 retinoic acid induced 14 3.284 Nucleus transcription regulator
CX3CL1 chemokine (C-X3-C motif) ligand 1 −2.044 Extracellular Space cytokine
PTGER3 prostaglandin E receptor 3 (subtype EP3) 2.425 Plasma Membrane G-protein coupled receptor
PI4K2A phosphatidylinositol 4-kinase type 2 alpha 2.96 Cytoplasm kinase
CD36 CD36 molecule (thrombospondin receptor) 5.08 Plasma Membrane transmembrane receptor
ARL11 ADP-ribosylation factor-like 11 3.143 Other other
Brd4 bromodomain containing 4 −3.528 Nucleus other
CLN5 ceroid-lipofuscinosis, neuronal 5 2.041 Cytoplasm other
Ctdspl CTD (carboxy-terminal domain, RNA polymerase II,
polypeptide A) small phosphatase-like
−7.271 Cytoplasm other
KIFAP3 kinesin-associated protein 3 −2.281 Cytoplasm other
Nos1ap nitric oxide synthase 1 (neuronal) adaptor protein −2.698 Other other
PCDH15 protocadherin-related 15 2.147 Plasma Membrane other
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TBI-C: A total of 115 GOI were identified. Our analysis
showed that 78 of the GOI formed an interconnected net-
work, leaving 37 “orphan” genes (see Additional file 5).
Genes having 1st order connections with more than 10 %
of the other genes within the main GOI network (>8 con-
nections) were considered “primary” in this analysis (see
Fig. 9 for an example). Genes having connections with
5 %–10 % of the other genes (4–8 connections) were con-
sidered “secondary” (see Additional file 6 for an example)
and those with connections with less than 5 % of the other
genes (<4 connections) were considered “peripheral”. The
resultant GIH is displayed in Table 7.
Cell cycle genes included in the GIHs
We performed an IPA molecular and cellular functional
analysis on the unranked GOI for both datasets and the
top 2 tiers (most significant by our definition) of our re-
sultant GIHs to further elucidate the most significant
biological functions post-TBI (Fig. 10). The cell death and
survival category was removed from this analysis since all
genes were initially selected from this functional category.
When analyzing the top 2 tiers of the GIHs, cell cycle was
ranked second for TBI-I and first for TBI-C. Is was also the
highest ranked molecular and cellular function common to
both sides (Fig. 10 b, d). The cell cycle moved up 5 func-
tional ranking spots on both sides of the brain from where
it was ranked prior to the GIH analysis. This result was in-
triguing because aberrant attempts to reactivate the cell
cycle by post-mitotic neurons have been implicated as a
trigger for apoptosis [26, 27]. By cross-referencing our
GIHs with genes that IPA includes in the cell cycle upper
level biological function, we determined that 74 genes in
the TBI-I GIH and 47 genes in the TBI-C GIH were associ-
ated with the cell cycle (Tables 8 and 9). Just over 85 % of
the cell cycle genes increased in expression ipsilaterally
compared to controls. The relative inverse is true contralat-
erally with nearly 79 % of the cell cycle genes decreasing in
expression. Remarkably, 83 % of TBI-I and 70 % of TBI-C
primary and secondary tier genes were classified as cell
cycle genes (TBI-I: 35 of 42 genes; TBI-C: 19 of 27 genes).
Real-time PCR
As expected, ipsilateral expression was significantly in-
creased compared to naïve for all genes tested following
TBI (Fig. 11). However, ipsilateral expression was only sig-
nificantly different from contralateral expression for SPP1
and HSPB1 while this comparison for STAT3 (p = 0.088)
and CCND1 (p = 0.063) fell short of statistical significance.
Contralateral expression was not significantly different
from naïve for any of the genes tested.
Discussion
We used microarray technology and subsequent bio-
informatic analysis in this study to examine molecular
and functional alterations following TBI. Not surpris-
ingly, cell death and survival was determined to be a sig-
nificant molecular and cellular function associated with
the genes expressed ipsilateral to the injury. Interest-
ingly, while cell death was not observed on the contra-
lateral side of the brain, there was significant modulation
of cell death and survival genes and this molecular and
cellular function is very highly associated with the gene
expression pattern.
Our histology results using markers for cell damage
(FJB) and DNA fragmentation (TUNEL) suggest a poten-
tial opportunity for therapeutic intervention. At 24 h post-
injury, there is a developing cortical cavity at the site of
impact surrounded with FJB and TUNEL-positive cells.
Therapy aimed at preserving cortical tissue should be
administered in the acute period to exert maximal neuro-
protective effects. However, while there is significant cor-
relation between FJB and TUNEL staining in the cortex at
this time point, no TUNEL-positive cells were detected in
the hippocampus where FJB detected some neuronal dam-
age on the ipsilateral side. Similar histology results were
recently seen with our model of nerve agent exposure [20]
and a neuroprotective agent was able to rescue the hippo-
campal neurons [28]. This suggests that these hippocam-
pal neurons have not yet progressed to the point of
apoptosis and an extended therapeutic window may exist
for subcortical brain areas.
Our microarray data showed that TBI resulted in signifi-
cant alterations in CD gene expression on both sides of
the brain. Nearly 45 % of the differentially expressed CD
genes were common to both sides of the brain and 82 %
of those genes changed similarly. However, a distinct
expression pattern was exhibited by the balance of the
common CD genes and those that change in expression
Table 6 TBI-I Gene interaction hierarchy (GIH) (Continued)
RASSF4 Ras association (RalGDS/AF-6) domain family member 4 4.289 Other other
Rbm25 RNA binding motif protein 25 −5.547 Nucleus other
Slpi secretory leukocyte peptidase inhibitor 82.908 Cytoplasm other
Tpm3 tropomyosin 3 2.592 Cytoplasm other
TRIM54 tripartite motif containing 54 −4.426 Cytoplasm other
Primary: >14 connections in GOI network (see text); Secondary: 8–14 connections in GOI network; Peripheral: <8 connections in GOI network; Orphan: No
connections in GOI network; Italics= > Gene changes on both sides of the brain
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uniquely on one side of the brain. The vast majority of
these ipsilateral CD genes increased in expression com-
pared to controls, while the majority of these contralateral
CD genes decreased in expression compared to controls
or were reduced compared to ipsilateral expression. Not-
able was the expression of key apoptosis-related genes.
BCL2A1, caspases 3 and 7, CDK1, cyclins A2 and D1, and
NFKB2 showed increased expression ipsilaterally, while
BAX, cyclins D1and D2, KRAS and PIK3CD showed
decreased expression contralaterally.
It is important to note here that the real-time PCR
results for the genes selected did not agree totally
with the microarray results. This was especially true
for the contralateral samples. However, it has been
shown that the correlation between microarray and
real-time PCR results is lower for genes showing
Fig. 9 An example of calculating the number of direct connections for the TBI-C GOI network. In IPA, the gene in question was selected (SOX2 in this
example). Then, its direct connections were selected by right clicking on SOX2 and using the “select nearest neighbors” option (highlighted in blue).
A list of the selected genes was exported and SOX2 was removed from the list (upper right corner). The remaining genes were counted (13 in this
example) and SOX2 was ranked in the TBI-C gene interaction hierarchy (primary tier) by this number
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Table 7 TBI-C Gene interaction hierarchy (GIH)
Gene
symbol






CCND1 cyclin D1 −2.027 Nucleus transcription regulator
MED1 mediator complex subunit 1 −4.011 Nucleus transcription regulator
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 4
−7.712 Nucleus transcription regulator
SOX2 SRY (sex determining region Y)-box 2 −4.791 Nucleus transcription regulator
SP1 Sp1 transcription factor −2.076 Nucleus transcription regulator
STAT3 signal transducer and activator of transcription 3 (acute-phase
response factor)
−3.771 Nucleus transcription regulator
CSNK2A1 casein kinase 2, alpha 1 polypeptide −2.75 Cytoplasm kinase
EGFR epidermal growth factor receptor 2.374 Plasma Membrane kinase
GSK3B glycogen synthase kinase 3 beta −6.635 Nucleus kinase
CD44 CD44 molecule (Indian blood group) 2.399 Plasma Membrane enzyme
HSP90AA1 heat shock protein 90 kDa alpha (cytosolic), class A member 1 −4.843 Cytoplasm enzyme
Secondary
FOXO1 forkhead box O1 −3.329 Nucleus transcription regulator
MEF2A myocyte enhancer factor 2A −6.31 Nucleus transcription regulator
NFIX nuclear factor I/X (CCAAT-binding transcription factor) −8.112 Nucleus transcription regulator
TCF4 transcription factor 4 −4.625 Nucleus transcription regulator
MAPK8 mitogen-activated protein kinase 8 2.102 Cytoplasm kinase
PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 2.332 Cytoplasm kinase
PTK2B protein tyrosine kinase 2 beta 2.15 Cytoplasm kinase
KRAS Kirsten rat sarcoma viral oncogene homolog −2.027 Cytoplasm enzyme
TOP2A topoisomerase (DNA) II alpha 170 kDa −2.406 Nucleus enzyme
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 −2.607 Cytoplasm transporter
BAX BCL2-associated X protein −3.306 Cytoplasm transporter
SPP1 secreted phosphoprotein 1 2.37 Extracellular Space cytokine
THRA thyroid hormone receptor, alpha −11.518 Nucleus ligand-dependent nuclear
receptor
TUFM Tu translation elongation factor, mitochondrial −2.109 Cytoplasm translation regulator
CCND2 cyclin D2 −3.617 Nucleus other
HSPB1 heat shock 27 kDa protein 1 2.639 Cytoplasm other
Peripheral
BTG2 BTG family, member 2 −5.803 Nucleus transcription regulator
CCAR1 cell division cycle and apoptosis regulator 1 −11.648 Nucleus transcription regulator
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 2.037 Nucleus transcription regulator
DEK DEK proto-oncogene −7.352 Nucleus transcription regulator
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 5.614 Nucleus transcription regulator
GBX2 gastrulation brain homeobox 2 2.59 Nucleus transcription regulator
KLF6 Kruppel-like factor 6 2.865 Nucleus transcription regulator
MAFG v-maf avian musculoaponeurotic fibrosarcoma oncogene
homolog G
−2.632 Nucleus transcription regulator
MTDH metadherin −2.544 Cytoplasm transcription regulator
PA2G4 proliferation-associated 2G4, 38 kDa −5.783 Nucleus transcription regulator
RSF1 remodeling and spacing factor 1 −2.618 Nucleus transcription regulator
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Table 7 TBI-C Gene interaction hierarchy (GIH) (Continued)
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 −2.134 Nucleus transcription regulator
ZMYND11 zinc finger, MYND-type containing 11 −2.211 Nucleus transcription regulator
ZNF148 zinc finger protein 148 2.114 Nucleus transcription regulator
ACIN1 apoptotic chromatin condensation inducer 1 −2.515 Nucleus enzyme
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 4.808 Cytoplasm enzyme
DPYD dihydropyrimidine dehydrogenase 2.292 Cytoplasm enzyme
MFN1 mitofusin 1 2.304 Cytoplasm enzyme
MX1 MX dynamin-like GTPase 1 7.326 Cytoplasm enzyme
SETD8 SET domain containing (lysine methyltransferase) 8 −3.93 Nucleus enzyme
TTLL1 tubulin tyrosine ligase-like family, member 1 2.284 Extracellular Space enzyme
ACVR1C activin A receptor, type IC −9.107 Plasma Membrane kinase
CARD11 caspase recruitment domain family, member 11 2.892 Cytoplasm kinase
CDK11A cyclin-dependent kinase 11A −14.872 Nucleus kinase
CDK19 cyclin-dependent kinase 19 −2.191 Nucleus kinase
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
delta
−2.113 Cytoplasm kinase
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit −2.546 Cytoplasm kinase
SRPK2 SRSF protein kinase 2 −23.589 Nucleus kinase
PPP3CB protein phosphatase 3, catalytic subunit, beta isozyme 2.1 Plasma Membrane phosphatase
PTPRF protein tyrosine phosphatase, receptor type, F −20.492 Plasma Membrane phosphatase
IL6ST interleukin 6 signal transducer −3.283 Plasma Membrane transmembrane receptor
PRLR prolactin receptor −3.192 Plasma Membrane transmembrane receptor
LCN2 lipocalin 2 3.895 Extracellular Space transporter
RASA1 RAS p21 protein activator (GTPase activating protein) 1 −2.105 Cytoplasm transporter
TIMP1 TIMP metallopeptidase inhibitor 1 2.101 Extracellular Space cytokine
EIF5B eukaryotic translation initiation factor 5B −8.766 Cytoplasm translation regulator
AHI1 Abelson helper integration site 1 −2.897 Cytoplasm other
CDT1 chromatin licensing and DNA replication factor 1 −2.295 Nucleus other
CISD2 CDGSH iron sulfur domain 2 −19.012 Cytoplasm other
GADD45G growth arrest and DNA-damage-inducible, gamma −2.384 Nucleus other
HLA-A major histocompatibility complex, class I, A 3.657 Plasma Membrane other
LINGO1 leucine rich repeat and Ig domain containing 1 −2.173 Plasma Membrane other
MAFB v-maf avian musculoaponeurotic fibrosarcoma oncogene
homolog B
−2.018 Nucleus other
PHLDA1 pleckstrin homology-like domain, family A, member 1 2.16 Cytoplasm other
PMEPA1 prostate transmembrane protein, androgen induced 1 −2.937 Plasma Membrane other
PSIP1 PC4 and SFRS1 interacting protein 1 2.113 Nucleus other
RAD23B RAD23 homolog B (S. cerevisiae) −2.217 Nucleus other
RASSF4 Ras association (RalGDS/AF-6) domain family member 4 2.106 Other other
RDX radixin −5.274 Cytoplasm other
Serbp1 Serpine1 mRNA binding protein 1 −2.059 Cytoplasm other
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 3
2.509 Extracellular Space other
Orphan
AURKAIP1 aurora kinase A interacting protein 1 −2.023 Nucleus enzyme
CP ceruloplasmin (ferroxidase) 8.477 Extracellular Space enzyme
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decreased expression and having lower fold changes [29].
Our results do show better correlation with the large TBI-I
fold change genes SPP1 (37.9 fold) and HSPB1 (46.9 fold).
The remaining fold changes for the selected genes are less
than ± 4.22 with most in the 2.0-2.6 range. While further
validation including more genes and a larger sample size
may be needed for subsequent studies, these PCR results
are consistent with expression of these genes being higher
for TBI-I and lower for TBI-C. It is in this context that the
discussion of the microarray results continues.
As stated above, this contralateral expression pattern in
our model may indicate an endogenous effort to suppress
Table 7 TBI-C Gene interaction hierarchy (GIH) (Continued)
EHD4 EH-domain containing 4 −2.056 Plasma Membrane enzyme
ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5 −2.055 Cytoplasm enzyme
KIF3A kinesin family member 3A −11.754 Cytoplasm enzyme
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex,
1, 8 kDa
−2.028 Cytoplasm enzyme
PDE4B phosphodiesterase 4B, cAMP-specific 2.359 Cytoplasm enzyme
RND3 Rho family GTPase 3 −2.971 Cytoplasm enzyme
SDC1 syndecan 1 2.566 Plasma Membrane enzyme
SRXN1 sulfiredoxin 1 2.402 Cytoplasm enzyme
ATRX alpha thalassemia/mental retardation syndrome X-linked −5.964 Nucleus transcription regulator
KLF13 Kruppel-like factor 13 −4.582 Nucleus transcription regulator
NAA15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit −3.751 Nucleus transcription regulator
KCND2 potassium voltage-gated channel, Shal-related subfamily, mem-
ber 2
−7.585 Plasma Membrane ion channel
KCNN4 potassium intermediate/small conductance calcium-activated
channel, subfamily N, member 4
−9.429 Plasma Membrane ion channel
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 −23.824 Plasma Membrane kinase
TRPM7 transient receptor potential cation channel, subfamily M, member 7 2.226 Plasma Membrane kinase
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 2.276 Plasma Membrane transporter
TPR translocated promoter region, nuclear basket protein −2.728 Nucleus transporter
FGL2 fibrinogen-like 2 4.017 Extracellular Space peptidase
EIF3C eukaryotic translation initiation factor 3, subunit C −9.072 Other translation regulator
Brd4 bromodomain containing 4 −15.202 Nucleus other
CCDC86 coiled-coil domain containing 86 −2.149 Nucleus other
CD68 CD68 molecule 2.007 Plasma Membrane other
CDH13 cadherin 13 −2.692 Plasma Membrane other
CMIP c-Maf inducing protein −13.763 Cytoplasm other
Ctdspl CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A)
small phosphatase-like
−36.886 Cytoplasm other
KIFAP3 kinesin-associated protein 3 −7.831 Cytoplasm other
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 2.799 Cytoplasm other
LSP1 lymphocyte-specific protein 1 2.14 Cytoplasm other
Nos1ap nitric oxide synthase 1 (neuronal) adaptor protein −5.717 Other other
PALLD palladin, cytoskeletal associated protein −5.086 Plasma Membrane other
Rbm25 RNA binding motif protein 25 −16.213 Nucleus other
Slpi secretory leukocyte peptidase inhibitor 3.119 Cytoplasm other
THOC2 THO complex 2 −4.886 Nucleus other
Tpm3 tropomyosin 3 −2.715 Cytoplasm other
TRIM54 tripartite motif containing 54 −2.032 Cytoplasm other
Primary: >8 connections in GOI network (see text); Secondary: 4–8 connections in GOI network; Peripheral: <4 connections in GOI network; Orphan: No
connections in GOI network; Italics= > Gene changes on both sides of the brain
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cell death promoting genes remote from the injury in
order to prevent spreading of the injury and offer add-
itional protection from additional insults, similar to
gene expression changes in ischemic preconditioning
[30, 31]. An analogous and potentially neuroprotective
gene expression pattern was observed in an in vitro model
of mild TBI where the modulation of genes reflected an
endogenous effort to prevent oxidative/nitrosative stress
and apoptosis during a transient period of mitochondrial
malfunctioning [32]. We have previously reported a similar
gene expression pattern for inflammatory response genes
following TBI [12]. In that previous study, genes from both
sides of the brain were pooled for analysis. Because we
now believe that analyzing gene expression on the contra-
lateral side is critical to understanding endogenous pro-
tective mechanisms, the full GIH analysis [33] was
performed on each side of the brain separately. By deter-
mining the key molecules involved in the endogenous ef-
fort to suppress cell death, it may be possible to develop
molecular strategies to provide neuroprotection for the
injured brain as well as augment the endogenous neuro-
protective process.
We identified 170 TBI-I and 115 TBI-C GOI through
canonical pathway and network analysis combined with
the common genes that change differently on each side
of the brain. Many of these genes have been previously
associated with acute brain injuries (i.e., TBI, stroke) but
not all of them have been connected to the cell death
caused by these injuries. These genes include BAX,
CASP3, CCNA2, CCND1, CD44, CD68, CEBPD,
GSK3B, HSPB1, IL1B, LCN2, NFKB2, SERPINA3, SPP1,
STAT3, TIMP1, TNFRSF1A, and TOP2A [14, 34–42].
This supported the idea that our methods for identifying
genes of interest targets important genes in the post-
injury response. Several genes which have been linked to
cell death in cancer, epilepsy, or psychological disorders
but not yet associated with brain injury, including
CSNK2A1, ELAVL1, MITF, and SMARCA4, were also
identified which may provide additional therapeutic tar-
gets for prevention of cell death following TBI. We next
Fig. 10 Functional analysis of GOI and top 2 GIH tiers. The top 10 molecular and cellular functions determined by IPA to be associated with the unranked
GOI for TBI-I (a) and TBI-C (c) and the primary and secondary tiers of the TBI-I (b) and TBI-C (d) GIHs. Side by side comparison allowed for visualization of how
functions changed in significance order once the genes were put into a ranked order. Notably, cell cycle moved up to be ranked second on both sides of
the brain. The cell death and survival category was removed from this analysis because all genes were initially selected from that functional category
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wanted to determine which genes were central to cell
death processes. We approached this by creating a net-
work of our GOI within IPA and determining how many
1st order connections each gene had with the other
genes in the network. A GIH was created based on these
numbers and distinct patterns in terms of molecular
type were found.
For TBI-I, transcription regulators were the predomin-
ant molecular type in the top 2 tiers of the GIH. This re-
sult was expected from our previous GIH analyses [12].
After the transcription regulators, kinases and unspecified
enzymes were prominent in the top 2 tiers of the TBI-I
GIH. In the peripheral tier, unspecified enzymes, tran-
scription regulators and kinases were most represented.
Cytokines, transmembrane receptors, and transporters
also had notable numbers in the peripheral tier. Remark-
ably, only 2 cytokines, IL1B and SPP1, are included in the
top 2 tiers of this GIH. This result is not unexpected as
previous GIH analysis had shown that the near 1-to-1 re-
lationship that cytokines have with their receptors limits
the 1st order connections these molecules have in the
GOI network [12].
Transcription regulators were also predominant in the
top 2 tiers of the TBI-C GIH followed by kinases and
unspecified enzymes. These same molecular types
headed the peripheral tier as well with transcription reg-
ulators ahead of enzymes and kinases. Other notable
molecular types in the peripheral tier were phosphatases,
transmembrane receptors, and transporters. Again, cyto-
kines do not have significant numbers in this GIH. Our
analysis strongly suggests that other molecular types,
transcription regulators, kinases, and other enzymes in
this case, may be better therapeutic targets because they
have the potential to impact the overall cell death
process to a greater extent.
Very intriguing in our cell death analysis was how cell
cycle moved up significantly in functional ranking on
both sides of the brain when comparing the functional
analysis for unranked GOI to that for the top 2 tiers of
our GIHs. Cell cycle molecules have be implicated as
apoptotic mediators for post-mitotic cells under stress
due to trauma or neurological disease. It is believed that
there is an aberrant attempt the re-enter the cell cycle
that causes the cells to eventually undergo apoptosis [26,
43–48]. Much attention has been given to the cyclin-
dependent kinases (CDKs), cyclins, which activate the
CDKs [27, 48, 49], and CDK inhibitors. Significant evi-
dence for CDK involvement in cell cycle-related apop-
tosis has come from the experimental use of exogenous
CDK inhibitors that prevented apoptosis [47, 50–56].
Pertinent to this discussion, evidence has shown that
CDK1, when activated by cyclin A [57], and CDK4 and
CDK6, when activated by cyclin D in post-mitotic neu-
rons, can lead to cell death via caspase-dependent apop-
tosis [26, 27, 44, 49]. Additionally, ablation of cyclin D1
reduces neurodegeneration caused by TBI [58]. CDK11
has been shown to initiate apoptosis by interacting with
either cyclin D3 [59] or eukaryotic translation initiation
factor 3 subunit F (EIF3F) [60]. In our model, cyclins
A2 and D1 are increased ipsilaterally, consistent with
other studies [27, 47, 50], while both cyclins D1 and
D2 are decreased contralaterally. CDK1 and the
CDK4 inhibitors, CDKN1A (p21,Cip1 (not in GIH))
and CDKN1B (p27,Kip1), are all increased ipsilater-
ally. CDK11 (CDK11A (both sides); CDK19 (TBI-C
Table 8 Cell cycle genes in the TBI-I gene interaction hierarchy
by tier
Primary Secondary Peripheral Orphan
ATF3 BAG3 BCL2A1 NEK6 ATRX
CASP3 CASP7 BTG2 NFIX Brd4
CCND1 CCNA2 CAMK2N1 PA2G4 CYP1B1
CD44 CDKN1B Ccl2 PDLIM7
CDK1 CEBPD CDK11A PMEPA1
CEBPB CREM CDT1 PRDM2
CREB1 FOSL1 DEK PTPRF
CREBBP HSPA1A/HSPA1B ETV5 RAB35
CSNK2A1 HSPB1 FGF2 SETD8
EGFR IKBKB FLNA SRPK2
ELAVL1 IL1B GADD45G SUDS3
FN1 KLF4 HMOX1 TBL1XR1
GSK3B KPNB1 HSPA2 TCEB3
MDM2 MCL1 IL6R THOC2
NFE2L2 MCM2 KLF6 TIMP1
SMARCA4 MITF LATS1 TNFRSF1A
STAT3 PTGS2 MCM8 TOP2A
SPP1 MMS22L TPR
Table 9 Cell cycle genes in the TBI-C gene interaction hierarchy
by tier
Primary Secondary Peripheral Orphan
CCND1 BAX ACIN1 MTDH ATRX
CD44 CCND2 BTG2 PA2G4 Brd4
CSNK2A1 FOXO1 CDK11A PMEPA1 CAMK2N1
EGFR HSPB1 CDK19 PRKAA2 CDH13
GSK3B KRAS CDT1 PTPRF ENTPD5
SMARCA4 MAPK8 CEBPD RSF1 THOC2
SOX2 NFIX CYP1B1 SETD8 TPR
SP1 PTK2B DEK SRPK2
STAT3 SPP1 GADD45G TBL1XR1
TOP2A KLF6 TIMP1
MAFB
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only)) decreases in expression on both sides of the
brain. While not found in our analysis, EIF3F is part
of the functional core of EIF along with EIF3A (TBI-
C only (not in GIH)) and EIF3C (both sides) which
decrease in expression following TBI [61]. It is plaus-
ible that apoptosis would occur in this injury state
because these molecules are not being expressed in
the tightly controlled manner necessary to properly
navigate the cell cycle [46, 55]. Other CDKs have also
been implicated in apoptosis and excitotoxic cell
death [26, 49, 51, 52, 62, 63] but our GIH does not
point to those as major players.
In addition to 4 TBI-I and 2 TBI-C CDK-related
genes, IPA classified 31 other TBI-I genes and 17
other TBI-C genes in the top 2 tiers of their respect-
ive GIHs as cell cycle genes. It should be noted that
cell cycle is an upper level function in IPA. That
means these genes, while associated with the cell
cycle, are not necessarily integral to its progression.
These genes fell into 3 general categories. The first
category included those genes that have been experi-
mentally linked to a model of TBI. Genes in this category
were ATF3, BAG3, CASP3, CASP7, CD44, CEBPB,
CEBPD, CREB1, CREM, EGFR, FN1, FOSL1, GSK3B,
HSPA1A/HSPA1B, HSPB1, IKBKB, IL1B, KLF4, MCL1,
MDM2, NFE2L2, PTGS2, SPP1, and STAT3 for TBI-I [22,
36, 40–42, 64–78] and BAX, CD44, EGFR, FOXO1,
GSK3B, HSPB1, MAPK8, SOX2, SPP1, and STAT3 for
TBI-C [22, 36, 40, 41, 67, 71, 78–81]. The second category
included genes that had been observed in models of hyp-
oxia/ischemia, chemical brain lesions, or spinal cord in-
jury. Genes in this category were CREBBP and KPNB1 for
TBI-I [82, 83] and KRAS, PTK2B, SP1, and TOP2A for
TBI-C [84–87]. The third category included genes that
were previously linked only to the progression of cancers
or psychotic disorders and, therefore, novel to a discussion
of cell death following TBI. Genes in this category were
CSNK2A1, ELAVL1, MCM2, MITF, and SMARCA4 for
TBI-I and CSNK2A1, NFIX, and SMARCA4 for TBI-C.
The specifics of how these genes are associated with the
cell cycle and affect cell death are beyond the scope of this
analysis. However, our GIH analysis would suggest that
these genes would be intriguing targets for further study
in relation to post-TBI cell death. Specifically, CCND1,
CSNK2A1, SMARCA4, and STAT3 were included in the
top 2 tiers for both datasets and exhibit increased
Fig. 11 Real-time PCR results for selected genes. SPP1, HSPB1, STAT3, and CCND1 were chosen for real-time PCR studies. Using the ΔΔCt method, the
normalized target gene expression level was given by 2-ΔΔCt. For all genes, ipsilateral (IPSI) expression was significantly different from naïve (a-d). Ipsilateral
expression was also significantly different from contralateral (CONTRA) expression for SPP1 (a) and HSPB1 (b). The comparison of ipsilateral to
contralateral expression for STAT3 (c; p = 0.088) and CCND1 (d; p = 0.063) fell short of statistical significance. Contralateral expression was not
significantly different from naïve for any genes. The results are shown as mean ± SE. * p < 0.05, ** p < 0.01, *** p < 0.005
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expression in TBI-I and decreased expression in TBI-C.
Additionally, cyclin D2 and 2 apoptosis signaling genes,
BAX and KRAS, are in the secondary tier of the TBI-
C GIH and show decreased expression. Targeting
these key molecules showing contralateral suppression
for potential therapies may prove effective because
their expression correlates to the observed absence of
cell death.
Conclusions
Unilateral TBI results in significant gene expression
changes on both sides of the brain. The overall gene ex-
pression pattern in the brain suggests a suppression of CD
genes contralateral to the injury which may be an endogen-
ous protective mechanism. Using canonical pathways and
IPA generated networks as a guide, we were able to identify
genes that were central to the post-TBI CD gene response.
Further network analysis allowed for the ranking of these
genes into GIHs. The GIH ranking then led to the identifi-
cation of cell cycle as a key molecular and cellular function
on both sides of the brain. Significantly, several cell cycle
molecules were identified in this analysis that exhibit
increased expression ipsilaterally and decreased expression
contralaterally. GIH analysis relies on connections in a
virtual network. Future experiments will use discrete mi-
crodissected portions of the brain (cortex, hippocampus,
striatum) in order to increase the likelihood that the
molecular interactions described in the network actually
do occur in vivo. This will increase the power of the GIH
analysis. Further real-time PCR confirmation will be neces-
sary with an emphasis on contralateral and decreased gene
expression. Also, proteomic confirmation will be necessary
to show that in vivo protein levels match our microarray
results [88, 89]. Once confirmed, the key CD molecules
suggested by our GIH can be further explored. Additional
exploration into the remote suppression of CD genes may
provide insight into neuroprotective mechanisms that
could be used to develop therapies to prevent cell death
following TBI.
Additional files
Additional file 1: Examples of TBI-I networks. TBI-I CD networks 1
(A), 3 (B), 5 (C), and 6 (D) (see Table 2) with all gene families, groups and
complexes expanded to show the member genes and showing the relative
expression values of potential GOI for TBI-I. red: relative increase in expression;
green: relative decrease in expression; white: no change in expression; gold
connections and outlines: expansion of gene families, groups and complexes
in the original network. (TIF 4.06 mb)
Additional file 2: Examples of TBI-C networks. TBI-C CD networks 1
(A), 3 (B), 5 (C), and 6 (D) (see Table 3) with all gene families, groups and
complexes expanded to show the member genes and showing the relative
expression values of potential GOI for TBI-C. red: relative increase in expression;
green: relative decrease in expression; white: no change in expression; gold
connections and outlines: expansion of gene families, groups and complexes
in the original network. (TIF 4.30 mb)
Additional file 3: The TBI-I GOI network. This is the resultant network
when IPA connected our 170 TBI-I GOI using only direct (1st order)
connections between the genes. 145 of the GOI formed an interconnected
network, leaving 25 “orphan” genes. (TIF 4.20 mb)
Additional file 4: An example of calculating the number of direct
connections for the TBI-I GOI network. In IPA, the gene in question
was selected (HSPB1 in this example). Then, its direct connections were
selected by right clicking on HSPB1 and using the “select nearest neighbors”
option (highlighted in purple). A list of the selected genes was exported
and HSPB1 was removed from the list (upper right corner). The remaining
genes were counted (11 in this example) and HSPB1 was ranked in the TBI-I
gene interaction hierarchy (secondary tier) by this number. (TIF 3.99 mb)
Additional file 5: The TBI-C GOI network. This is the resultant network
when IPA connected our 115 TBI-C GOI using only direct (1st order)
connections between the genes. 78 of the GOI formed an interconnected
network, leaving 37 “orphan” genes. (TIF 4.84 mb)
Additional file 6: An example of calculating the number of direct
connections for the TBI-C GOI network. In IPA, the gene in question
was selected (CCND2 in this example). Then, its direct connections were
selected by right clicking on CCND2 and using the “select nearest neighbors”
option (highlighted in purple). A list of the selected genes was exported and
CCND2 was removed from the list (upper right corner). The remaining genes
were counted (6 in this example) and CCND2 was ranked in the TBI-C gene
interaction hierarchy (secondary tier) by this number. (TIF 4.69 mb)
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